Physician profile
Brandy Nokes
NPI 1457873150
$3,580.66
in general payments reported to CMS, 2019-2025
12 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.69 · 2022: $336 · 2023: $927 · 2024: $720 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,208.56 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $627.60 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $488.05 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $470.11 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $441.08 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $403.27 | 2023-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $365.15 | 2022-2025 | |
| Alkermes, INC. | $350.28 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $248.31 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $92.15 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $38.91 | 2022-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $37.29 | 2022-2025 | Qelbree |
| Axsome Therapeutics, INC. | $18.46 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Nokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.